4.7 Article

Kirkiin: A New Toxic Type 2 Ribosome-Inactivating Protein from the Caudex of Adenia kirkii

Journal

TOXINS
Volume 13, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/toxins13020081

Keywords

Adenia; apoptosis; kirkiin; lectins; neuroblastoma; ribosome-inactivating proteins; ricin; toxic enzymes

Funding

  1. Alma Mater Studiorum, University of Bologna
  2. Pallotti Legacies for Cancer Research
  3. Fondazione CARISBO [2019.0539]
  4. Consejeria de Educacion, Junta de Castilla y Leon [VA033G19]

Ask authors/readers for more resources

Ribosome-inactivating proteins (RIPs) are plant toxins that damage ribosomes irreversibly, with type 2 RIPs being particularly cytotoxic due to the linkage of active A chains to lectin B chains. Kirkiin, a newly discovered type 2 RIP, not only inhibits protein synthesis and induces apoptosis in neuroblastoma cells at very low doses, but also shows potential for pharmacological applications in neurodegenerative studies and cancer therapy.
Ribosome-inactivating proteins (RIPs) are plant toxins that irreversibly damage ribosomes and other substrates, thus causing cell death. RIPs are classified in type 1 RIPs, single-chain enzymatic proteins, and type 2 RIPs, consisting of active A chains, similar to type 1 RIPs, linked to lectin B chains, which enable the rapid internalization of the toxin into the cell. For this reason, many type 2 RIPs are very cytotoxic, ricin, volkensin and stenodactylin being the most toxic ones. From the caudex of Adenia kirkii (Mast.) Engl., a new type 2 RIP, named kirkiin, was purified by affinity chromatography on acid-treated Sepharose CL-6B and gel filtration. The lectin, with molecular weight of about 58 kDa, agglutinated erythrocytes and inhibited protein synthesis in a cell-free system at very low concentrations. Moreover, kirkiin was able to depurinate mammalian and yeast ribosomes, but it showed little or no activity on other nucleotide substrates. In neuroblastoma cells, kirkiin inhibited protein synthesis and induced apoptosis at doses in the pM range. The biological characteristics of kirkiin make this protein a potential candidate for several experimental pharmacological applications both alone for local treatments and as component of immunoconjugates for systemic targeting in neurodegenerative studies and cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available